CRISM Therapeutics (CRTX) Share Price, News & Analysis

Company Overview

CRISM Therapeutics Corporation is clinical stage company, having developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs. ChemoSeed, CRISM’s lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective. CRISM will initiate its registration-grade Phase 2 clinical trial of irinotecan-ChemoSeed in patients with surgically resectable glioblastoma in Q1 2026. For more information please visit: https://www.crismtherapeutics.com

Key Stats

• Today's Range: 10 to 12
• 50-Day Range: 8 to 12
• 52-Week Range: 5.64 to 29.40
• Volume: 438 shs
• Average Volume: 65,198 shs
• Market Capitalization: £4.07 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CRTX Stock Analysis - Frequently Asked Questions

How have CRTX shares performed this year?

CRISM Therapeutics' stock was trading at GBX 10 at the beginning of 2025. Since then, CRTX stock has increased by 1.9% and is now trading at GBX 10.19.

How were CRISM Therapeutics' earnings last quarter?

CRISM Therapeutics Corporation (LON:CRTX) released its earnings results on Monday, September, 15th. The company reported ($2.80) earnings per share for the quarter.

How do I buy shares of CRISM Therapeutics?

Shares of CRTX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Company Calendar

• Last Earnings: 9/15/2025
• Today: 10/17/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Basic Materials
• Industry: Other Industrial Metals & Mining
• Sub-Industry: N/A
• Current Symbol: LON:CRTX
• CIK: N/A
• Web: www.crismtherapeutics.com
• Phone: N/A
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): GBX (0.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -£792.20 thousand
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -13.12%
• Return on Assets: -26.77%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.56
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: £25 thousand
• Price / Sales: 162.85
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: GBX 43.03 per share
• Price / Book: 0.24

Miscellaneous

• Outstanding Shares: 39,962,000
• Free Float: N/A
• Market Cap: £4.07 million
• Optionable: N/A
• Beta: 0.81